EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour Immunostimulation

Victor I Seledtsov iD, Galina V Seledtsova, Adas Darinskas, Alexei von Delwig iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26167724 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Victor I Seledtsov und 3 weiteren Autor:innen. Beteiligte Einrichtung: Petrovsky National Research Centre of Surgery, 119991 Moscow, Russia. Hauptthemen laut MEDLINE: Neoplasms, Antibodies, Monoclonal, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overexpression of growth factor receptors and immunosuppressive molecules is a hallmark of many tumour cells, distinguishing them from normal tissue. This co-expression enables tumours both to exploit proliferative signalling and to evade immune surveillance. Here, we propose a strategy that employs a combination of monoclonal antibodies (mAbs) targeting two distinct antigens (Ags) at sub-cytotoxic doses. This approach aims to achieve a threshold cytotoxic density of immune complexes selectively on malignant cells expressing both target Ags, while sparing normal cells that express only one. Typically, the first target Ag may be a growth factor receptor, such as epidermal growth factor receptor (EGFR and HER1), epidermal growth factor receptor 2 (HER2), or vascular endothelial growth factor receptor 2 (VEGFR2), and the second, an immunoinhibitory molecule, such as programmed death-ligand 1 (PD-L1). Selective mAb-mediated tumour destruction is expected to enhance neoantigen (NeoAg) presentation to the immune system, while the blockade of PD-1/PD-L1 interactions should further stimulate anti-tumour immune responses. Notably, this strategy can be implemented using clinically approved therapeutic mAbs, potentially enabling rapid translation into clinical practice without extensive regulatory hurdles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalHumansAnimalsErbB ReceptorsImmunotherapyAntigens, NeoplasmErb-b2 Receptor Tyrosine KinasesB7-H1 Antigen

Stichwörter der Autor:innen

PD-L1growth factor receptorimmunostimulationtargeted cytotoxicitytherapeutic monoclonal antibodytumor-associated antigen

Substanzen

Antibodies, MonoclonalErbB ReceptorsAntigens, NeoplasmAntineoplastic Agents, ImmunologicalErb-b2 Receptor Tyrosine KinasesB7-H1 Antigen

Autor:innen und Institutionen

  • Petrovsky National Research Centre of Surgery, 119991 Moscow, Russia.
  • Institute for Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia.
  • National Cancer Institute, 08406 Vilnius, Lithuania.

ORCID-Profile: Victor I Seledtsov, Alexei von Delwig

Zitieren

APA

Seledtsov, V. I., Seledtsova, G. V., Darinskas, A., & von Delwig, A. (2025). Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour Immunostimulation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26167724

Vancouver

Seledtsov VI, Seledtsova GV, Darinskas A, von Delwig A. Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour Immunostimulation. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26167724

BibTeX
@article{Seledtsov2025,
  author = {Seledtsov, Victor I and Seledtsova, Galina V and Darinskas, Adas and von Delwig, Alexei},
  title = {Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour Immunostimulation},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26167724}
}
Kostenlos starten →